Ortho Clinical Diagnostics Holdings plc

Financial performance has remained strong, with revenue growing from $492.50M in Q2 2021 to $500.10M in Q1 2022. Gross profit continued to perform well, with margins at 50% in the latest quarter. Operating income reached $49.20M in Q1 2022, holding a steady 10% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at $128.60M. Net income rose to $14.80M, keeping EPS at $0.06. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.